{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:29:41Z","timestamp":1782102581524,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10072-024-07763-7","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T11:09:18Z","timestamp":1726052958000},"page":"5841-5848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-2419","authenticated-orcid":false,"given":"Berenice A.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Heriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerem\u00edas","family":"Ayerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Balbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Nadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Liwacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Luetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Casales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Piedrabuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Z\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Hryb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Leguizam\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Pagani Cassar\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Carrizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Pita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"M\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"2","key":"7763_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180","journal-title":"N Engl J Med"},{"issue":"2","key":"7763_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152\u2013158","journal-title":"JAMA Neurol"},{"issue":"6","key":"7763_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","volume":"263","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S (2016) Optimizing treatment success in multiple sclerosis. J Neurol 263(6):1053\u20131065","journal-title":"J Neurol"},{"issue":"1","key":"7763_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","volume":"16","author":"JD Lunemann","year":"2020","unstructured":"Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H (2020) Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16(1):56\u201362","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"7763_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, C.S. Group (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362(5):416\u201326","journal-title":"N Engl J Med"},{"issue":"12","key":"7763_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594\u20131604","journal-title":"Mult Scler"},{"issue":"1","key":"7763_CR7","first-page":"205521732311547","volume":"9","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Alonso M, Garcea O, Silva B (2023) Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Mult Scler J Exp Transl Clin 9(1):20552173231154710","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"7763_CR8","doi-asserted-by":"publisher","first-page":"104935","DOI":"10.1016\/j.msard.2023.104935","volume":"79","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L, Liguori NF, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Garcea O, Silva B (2023) Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina. Mult Scler Relat Disord 79:104935","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"7763_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdova E (2017) \u201cNo evident disease activity\u201d: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179\u20131187","journal-title":"Mult Scler"},{"issue":"9","key":"7763_CR10","first-page":"CD013606","volume":"9","author":"K Reeve","year":"2023","unstructured":"Reeve K, On BI, Havla J, Burns J, Gosteli-Peter MA, Alabsawi A, Alayash Z, Gotschi A, Seibold H, Mansmann U, Held U (2023) Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev 9(9):CD013606","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"7763_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1756285610385608","volume":"3","author":"R Gold","year":"2010","unstructured":"Gold R, Wolinsky JS, Amato MP, Comi G (2010) Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 3(6):351\u2013367","journal-title":"Ther Adv Neurol Disord"},{"key":"7763_CR12","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M, Italian MSR (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:17562864211019574","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"7763_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, Tomassini V, Wardle M, Pickersgill T, Robertson N, Tallantyre E (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536\u2013541","journal-title":"JAMA Neurol"},{"issue":"2","key":"7763_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand\u2019Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, M.S.S. Group (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175\u2013187","journal-title":"JAMA"},{"key":"7763_CR15","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.msard.2021.102945","volume":"52","author":"G Bose","year":"2021","unstructured":"Bose G, Rush C, Atkins HL, Freedman MS (2021) A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Relat Disord 52:102945","journal-title":"Mult Scler Relat Disord"},{"key":"7763_CR16","doi-asserted-by":"publisher","first-page":"104791","DOI":"10.1016\/j.msard.2023.104791","volume":"76","author":"WJ Brownlee","year":"2023","unstructured":"Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT (2023) Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Mult Scler Relat Disord 76:104791","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"7763_CR17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1177\/1352458517728812","volume":"24","author":"T Kalincik","year":"2018","unstructured":"Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand\u2019Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H, M.S.S. Group (2018) Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. Mult Scler 24(12):1617\u20131626","journal-title":"Mult Scler"},{"issue":"3","key":"7763_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1352458520921087","volume":"27","author":"N Lizak","year":"2021","unstructured":"Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T (2021) Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Mult Scler 27(3):465\u2013474","journal-title":"Mult Scler"},{"key":"7763_CR19","doi-asserted-by":"publisher","first-page":"104403","DOI":"10.1016\/j.msard.2022.104403","volume":"68","author":"L Negrotto","year":"2022","unstructured":"Negrotto L, Iut VC, Etchepare A, D\u2019Eramo M, Grinspan A, Assefi A (2022) High persistence and low adverse events burden in cladribine treated MS patients from Argentina. Mult Scler Relat Disord 68:104403","journal-title":"Mult Scler Relat Disord"},{"key":"7763_CR20","doi-asserted-by":"publisher","first-page":"577966","DOI":"10.1016\/j.jneuroim.2022.577966","volume":"372","author":"D Magalashvili","year":"2022","unstructured":"Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, Achiron A (2022) Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. J Neuroimmunol 372:577966","journal-title":"J Neuroimmunol"},{"key":"7763_CR21","doi-asserted-by":"publisher","first-page":"175628641988759","DOI":"10.1177\/1756286419887596","volume":"12","author":"N Mohn","year":"2019","unstructured":"Mohn N, Skripuletz T, Suhs KW, Menck S, Voss E, Stangel M (2019) Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Ther Adv Neurol Disord 12:1756286419887596","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"7763_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","volume":"11","author":"M Petracca","year":"2022","unstructured":"Petracca M, Ruggieri S, Barbuti E, Ianniello A, Fantozzi R, Maniscalco GT, Andreone V, Landi D, Marfia GA, Di Gregorio M, Iodice R, Sinisi L, Maida E, Missione R, Coppola C, Bonavita S, Borriello G, Centonze D, Lus G, Pozzilli C, Signoriello E (2022) Predictors of cladribine effectiveness and safety in multiple sclerosis: A real-world, multicenter, 2-year follow-up study. Neurol Ther 11(3):1193\u20131208","journal-title":"Neurol Ther"},{"key":"7763_CR23","doi-asserted-by":"publisher","first-page":"103755","DOI":"10.1016\/j.msard.2022.103755","volume":"61","author":"I Rauma","year":"2022","unstructured":"Rauma I, Viitala M, Kuusisto H, Atula S, Sipila JOT, Ryytty M, Soilu-Hanninen M, Jarvinen E (2022) Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord 61:103755","journal-title":"Mult Scler Relat Disord"},{"key":"7763_CR24","doi-asserted-by":"publisher","first-page":"104491","DOI":"10.1016\/j.msard.2022.104491","volume":"70","author":"PS Sorensen","year":"2023","unstructured":"Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schafer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M (2023) Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Mult Scler Relat Disord 70:104491","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"7763_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H (2023) Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Mult Scler 29(2):221\u2013235","journal-title":"Mult Scler"},{"issue":"3","key":"7763_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, M.S.S.G. oral cladribine for early (2014) Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 13(3):257\u201367","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"7763_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00687954","volume":"71","author":"CM Poser","year":"1986","unstructured":"Poser CM (1986) Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol (Berl) 71(1\u20132):1\u201310","journal-title":"Acta Neuropathol (Berl)"},{"key":"7763_CR28","unstructured":"Annovazzi FJP, Margoni M, Nozolillo A et al (2021) Two year relapse free and NEDA status with Cladribine in a real life population: a multicentre study. ECTRIMS 2021 congress. Mult Scler J 453"},{"key":"7763_CR29","unstructured":"Zanetta C, Sangalli F, Guerrieri S et al (2021) Efficacy\/safety profile of cladribine in an italian real-life cohort of relapsing remitting multiple sclerosis patients. EAN 2021. Eur J Neurol Abstract (EPR-179) 325"},{"issue":"7","key":"7763_CR30","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, Martinelli V, Ferre L, Moiola L, Filippi M (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol 270(7):3553\u20133564","journal-title":"J Neurol"},{"issue":"4","key":"7763_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, KubalaHavrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand\u2019Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T, M.S.s. group (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"key":"7763_CR32","doi-asserted-by":"publisher","first-page":"104459","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK, Magyari M, Selchen D, Vermersch P, Wiendl H, Van Wijmeersch B, Salloukh H, Yamout B (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459","journal-title":"Mult Scler Relat Disord"},{"key":"7763_CR33","unstructured":"Annovazzi P, Prosperini L, Capuano R et al (2020) Relapse-free and neda status with cladribine in a real life population: a multicentre study. ECTRIMS congress. Mult Scler J 551"},{"key":"7763_CR34","doi-asserted-by":"publisher","first-page":"101498","DOI":"10.1016\/j.msard.2019.101498","volume":"38","author":"T Mustonen","year":"2020","unstructured":"Mustonen T, Rauma I, Hartikainen P, Kruger J, Niiranen M, Selander T, Simula S, Remes AM, Kuusisto H (2020) Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. Mult Scler Relat Disord 38:101498","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"7763_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/13524585211012227","volume":"28","author":"S Pfeuffer","year":"2022","unstructured":"Pfeuffer S, Rolfes L, Hackert J, Kleinschnitz K, Ruck T, Wiendl H, Klotz L, Kleinschnitz C, Meuth SG, Pul R (2022) Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 28(2):257\u2013268","journal-title":"Mult Scler"},{"key":"7763_CR36","doi-asserted-by":"publisher","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809","journal-title":"Ther Adv Neurol Disord"},{"key":"7763_CR37","doi-asserted-by":"publisher","first-page":"103812","DOI":"10.1016\/j.msard.2022.103812","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skattebol L, Hogestol EA, Sowa P, Myhr KM, Torkildsen O, Celius EG (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 62:103812","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"7763_CR38","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","volume":"21","author":"SG Meuth","year":"2020","unstructured":"Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, Maurer M (2020) Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother 21(16):1965\u20131969","journal-title":"Expert Opin Pharmacother"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07763-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:11:08Z","timestamp":1731319868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07763-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7763"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07763-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the institutions involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None of the authors present conflicts of interest in relation to this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}